Prudential Upgrades CuraGen Rating to Buy
CuraGen Corp. (CRGN ) shares were sharply higher after the genomics research firm announced that it had entered into two alliances with pharmaceuticals giant Bayer. Prudential Securities upgraded its investment recommendation on the shares to strong buy from accumulate.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.